{"id":40487,"date":"2025-09-01T15:17:05","date_gmt":"2025-09-01T07:17:05","guid":{"rendered":"https:\/\/flcube.com\/?p=40487"},"modified":"2025-09-01T15:17:06","modified_gmt":"2025-09-01T07:17:06","slug":"fosun-pharma-secures-china-rights-to-accropeutics-ac%e2%80%91201-jak-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40487","title":{"rendered":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor"},"content":{"rendered":"\n<p>Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced today that it has entered into a comprehensive license agreement with U.S. biotech Accropeutics Bioscience. The deal grants Fosun exclusive rights to research, develop, manufacture, register, and market the AC\u2011201 molecule and any products containing AC\u2011201 as the active ingredient in Mainland China, Hong Kong SAR, and Macau SAR.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB\u202f60\u202fmillion<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to RMB\u202f96\u202fmillion contingent on regulatory and commercial milestones<\/td><\/tr><tr><td><strong>Sales\u2011Based Payments<\/strong><\/td><td>Tiered sales milestones and royalty payments tied to net sales within the licensed territories<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>RMB\u202f156\u202fmillion (up to)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-ac-201\">About AC\u2011201<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Structure<\/strong> \u2013 An orally administered, small\u2011molecule Janus Kinase (JAK) inhibitor engineered by Accropeutics Bioscience.<\/li>\n\n\n\n<li><strong>Indication Focus<\/strong> \u2013 Primarily targeted at autoimmune disorders, with Phase\u202f2 data in China demonstrating robust efficacy and safety in moderate\u2011to\u2011severe plaque psoriasis.<\/li>\n\n\n\n<li><strong>Development Trajectory<\/strong> \u2013 The molecule is poised for further clinical development and potential registration in the Chinese market under Fosun\u2019s umbrella.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-fosun\">Strategic Implications for Fosun<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong> \u2013 Adds a high\u2011potential immunology asset to Fosun\u2019s oncology\u2011centric pipeline.<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong> \u2013 Autoimmune diseases are a rapidly growing therapeutic segment in China; AC\u2011201\u2019s oral formulation and favorable safety profile could capture significant market share.<\/li>\n\n\n\n<li><strong>Financial Upside<\/strong> \u2013 The tiered royalty structure aligns long\u2011term revenue with product performance, offering upside potential beyond the upfront and milestone payments.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>Fosun will begin the regulatory registration process for AC\u2011201 in China immediately, with an expected filing window in Q1\u202f2026. Accropeutics will collaborate on pre\u2011clinical and Phase\u202f3 studies under Fosun\u2019s manufacturing and commercial platform.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600196_20250830_6IMC.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20250830_6IMC.\"><\/object><a id=\"wp-block-file--media-e20d022c-df2d-47b1-a3d0-93549cc2bceb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600196_20250830_6IMC.pdf\">600196_20250830_6IMC<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600196_20250830_6IMC.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e20d022c-df2d-47b1-a3d0-93549cc2bceb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[2772,65,159,893,892],"class_list":["post-40487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-accropeutics","tag-auto-immune","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"hina\u2011based Fosun Pharmaceutical (SHA: 600196, HKG: 2196) has signed an exclusive license with Accropeutics Bioscience for the research, development, and commercialization of AC\u2011201, a small\u2011molecule JAK inhibitor that completed Phase\u202f2 trials for plaque psoriasis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40487\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor\" \/>\n<meta property=\"og:description\" content=\"hina\u2011based Fosun Pharmaceutical (SHA: 600196, HKG: 2196) has signed an exclusive license with Accropeutics Bioscience for the research, development, and commercialization of AC\u2011201, a small\u2011molecule JAK inhibitor that completed Phase\u202f2 trials for plaque psoriasis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40487\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T07:17:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-01T07:17:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor\",\"datePublished\":\"2025-09-01T07:17:05+00:00\",\"dateModified\":\"2025-09-01T07:17:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487\"},\"wordCount\":281,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0107.webp\",\"keywords\":[\"Accropeutics\",\"Auto-immune\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40487#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40487\",\"name\":\"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0107.webp\",\"datePublished\":\"2025-09-01T07:17:05+00:00\",\"dateModified\":\"2025-09-01T07:17:06+00:00\",\"description\":\"hina\u2011based Fosun Pharmaceutical (SHA: 600196, HKG: 2196) has signed an exclusive license with Accropeutics Bioscience for the research, development, and commercialization of AC\u2011201, a small\u2011molecule JAK inhibitor that completed Phase\u202f2 trials for plaque psoriasis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40487\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0107.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0107.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40487#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"hina\u2011based Fosun Pharmaceutical (SHA: 600196, HKG: 2196) has signed an exclusive license with Accropeutics Bioscience for the research, development, and commercialization of AC\u2011201, a small\u2011molecule JAK inhibitor that completed Phase\u202f2 trials for plaque psoriasis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40487","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor","og_description":"hina\u2011based Fosun Pharmaceutical (SHA: 600196, HKG: 2196) has signed an exclusive license with Accropeutics Bioscience for the research, development, and commercialization of AC\u2011201, a small\u2011molecule JAK inhibitor that completed Phase\u202f2 trials for plaque psoriasis.","og_url":"https:\/\/flcube.com\/?p=40487","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-01T07:17:05+00:00","article_modified_time":"2025-09-01T07:17:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40487#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40487"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor","datePublished":"2025-09-01T07:17:05+00:00","dateModified":"2025-09-01T07:17:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40487"},"wordCount":281,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40487#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp","keywords":["Accropeutics","Auto-immune","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40487#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40487","url":"https:\/\/flcube.com\/?p=40487","name":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40487#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40487#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp","datePublished":"2025-09-01T07:17:05+00:00","dateModified":"2025-09-01T07:17:06+00:00","description":"hina\u2011based Fosun Pharmaceutical (SHA: 600196, HKG: 2196) has signed an exclusive license with Accropeutics Bioscience for the research, development, and commercialization of AC\u2011201, a small\u2011molecule JAK inhibitor that completed Phase\u202f2 trials for plaque psoriasis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40487#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40487"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40487#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp","width":1080,"height":608,"caption":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40487#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Secures China Rights to Accropeutics\u2019 AC\u2011201 JAK Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0107.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40487"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40487\/revisions"}],"predecessor-version":[{"id":40491,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40487\/revisions\/40491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40490"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}